Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
81.77
-0.06 (-0.07%)
At close: Dec 5, 2025, 4:00 PM EST
81.76
-0.01 (-0.01%)
After-hours: Dec 5, 2025, 6:05 PM EST
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 73.63, with a low estimate of 51 and a high estimate of 100. The average target predicts a decrease of -9.95% from the current stock price of 81.77.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +22.29% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +6.40% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $88 | Strong Buy | Maintains | $72 → $88 | +7.62% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | -11.95% | May 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $46 → $51 | Hold | Maintains | $46 → $51 | -37.63% | May 5, 2025 |
Financial Forecast
Revenue This Year
452.34M
from 182.95M
Increased by 147.24%
Revenue Next Year
692.58M
from 452.34M
Increased by 53.11%
EPS This Year
-1.53
from -3.07
EPS Next Year
1.82
from -1.53
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 467.5M | 815.5M | ||||
| Avg | 452.3M | 692.6M | ||||
| Low | 433.6M | 592.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 155.5% | 80.3% | ||||
| Avg | 147.2% | 53.1% | ||||
| Low | 137.0% | 30.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.38 | 3.37 | ||||
| Avg | -1.53 | 1.82 | ||||
| Low | -2.05 | 0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.